In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Apyx Medical (APYX – Research Report). The company’s shares closed yesterday at $2.97.
According to TipRanks, Hewitt is an analyst with an average return of -8.7% and a 35.47% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Repligen, and Streamline Health Solutions.
Apyx Medical has an analyst consensus of Moderate Buy, with a price target consensus of $3.89, implying a 30.98% upside from current levels. In a report released today, Lake Street also reiterated a Buy rating on the stock with a $3.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Apyx Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.98 million and a GAAP net loss of $4.63 million. In comparison, last year the company earned a revenue of $9.11 million and had a GAAP net loss of $5.76 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apyx Medical (APYX) Company Description:
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
Read More on APYX:
